OncoLink Cancer Treatment and Resources
Link to OncoLink

Preliminary Report of RTOG 9508: A Phase III Trial Comparing Whole Brain Irradiation Alone Versus Whole Brain Irradiation Plus Stereotactic Radiosurgery for Patients with Two or Three Unresected Brain Metastases

Joel W. Goldwein, MD
OncoLink co-Editor-In-Chief
Ultima Vez Modificado: 23 de octubre del 2000

Presenter: P. W. Sperduto
Affiliation: Radiation Therapy Oncology Group


Summary:

Brain metastases develop in approximately 25% of all cancer patients. Management with stereotactic radiotherapy for patients with 3 or less solitary lesions remains an area of controversy. This preliminary analysis is of a group of patients treated with whole brain radiation versus whole brain radiotherapy plus a radiosurgical boost.


Methods:

  • Patients with 2 or 3 solitary metastases were evaluated in this analysis

  • Patients were randomized to either 3750 cGy/15 fractions whole brain RT or 3750 cGy/15 fractions whole brain RT + 1500 cGy to 2400 cGy radiosurgical boost (size dependent)


Results:

  • The groups were well balanced for parameters such as KPS, numbers of lesions, and other factors

  • Median survival in the 2 arms were 5.8 and 6.7 months, and were not significantly different.

  • Local control was marginally better in the stereotactic boost arm vs. the whole brain alone arm

  • There was a 20% improvement in Karnofsky status in the radiosurgery arm versus 0% in the whole brain alone arm, and a similar reduction in steroid dependence among patients receiving boost RT.

  • There was no grade 4 or 5 toxicity in either arm, and 4% grade III toxicity in the boost arm versus 0% in the no-boost arm


Author's Conclusions:

  • In patients with 2 or 3 brain metastases, stereotactic boost following whole brain RT has no impact on survival, improves local control, and may improve quality of life


Clinical/Scientific Implications:

  • Patients with 2 or 3 brain metastases may benefit from such therapy in terms of local control and quality of life

  • Further study will be required to identify subsets of patients who derive the most benefit from this therapy.

OncoLink I wish u knew...

Dr. O'Dwyer discusses the role of genetics in cancer research and care. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS